Two new options for self-administration of Nucala now approved in Canada for patients with severe eosinophilic asthma.

Nucala (mepolizumab) has been approved in Canada in two new formats � a pre-filled auto-injector and a pre-filled safety syringe � for use by healthcare professionals, patients and their caregivers. These new formats provide the option for patients to self-administer Nucala at-home, upon approval and training from their healthcare professional, for the treatment of severe eosinophilic asthma (SEA) or eosinophilic granulomatosis with polyangiitis (EGPA).

Nucala is the first anti-IL5 biologic to be licensed in Canada for at-home administration, and the first respiratory biologic to be approved for administration through an autoinjector. IL-5 plays an important role in regulating the function of eosinophils, an inflammatory cell known to be active in asthma and EGPA.